Search results
Why Moderna Stock Blasted 13% Higher Today
Motley Fool via Yahoo Finance· 6 hours agoNormally, investors wouldn't reward such declines and steep shortfalls. But the market was braced for a notably worse showing. On average, analysts...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga via Yahoo Finance· 10 hours agoThursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 12 hours agoModerna stock broke out for the first time in over a year on May 2 after the biotech company notched...
Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views
Investor's Business Daily· 9 hours agoModerna stock broke out for the first time in a year on Thursday after beating Wall Street's...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 17 hours agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 17 hours agoModerna (MRNA) delivered earnings and revenue surprises of 14.48% and 33.88%, respectively, for the...
Moderna Stock Jumps After Scoring an Earnings Beat. Next Up? Its RSV Shot.
Barrons.com· 14 hours agoModerna reported first-quarter financial results Thursday that soundly beat Wall Street...
Moderna (MRNA) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 12 hours agoI'll now turn the call over to Stephane. Should you invest $1,000 in Moderna right now? Before you buy stock in Moderna, consider this ...
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Zacks via Yahoo Finance· 14 hours agoTotal revenues declined 91% year over year due to reduced COVID-19 vaccine sales during the quarter....
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 11 hours agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.